Healthcare DIVE September 14, 2021
Nick Paul Taylor

Dive Brief:

  • CMS is planning to scrap its contentious breakthrough payment rule after concluding it is not in the best interest of Medicare beneficiaries.
  • The Medicare Coverage of Innovative Technology (MCIT) pathway would have allowed medtech companies to secure near-automatic coverage for a period of four years with an FDA breakthrough device designation. However, after buying itself time to review the rule, CMS concluded there are “significant concerns” about the clinical evidence on breakthrough devices in the Medicare population.
  • AdvaMed said the proposed repeal is the “wrong decision” and will have the chance to make its case before the action is finalized. Nonetheless, the proposal could yet be resurrected through the second iteration of the 21st Century Cures Act...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: CMS, Govt Agencies, Insurance, Medical Devices, Medicare
CMS extends special enrollment period for persons no longer eligible for Medicaid, CHIP
39 physician specialties ranked by total pay from 2013-2022
1 Year Later: How Has the Unwinding of Medicaid Continuous Enrollment Gone?
Understanding CMS’ AHEAD Model: Medicare Hospital Global Budget Design and Implications
‘Borderline Useless’ CMS Data Needs an Overhaul, Starting with the Addition of Medicare Advantage to Cost Reports

Share This Article